1045730-24-2

Upstream product

• 545-06-2 trichloroacetonitrile 

Downstream Products

• 1384967-24-1 (2S,3S,4S,5R,6S)-2-((benzyloxy)carbonyl)-6-(2-ethoxy-4-((S)-2-(methylsulfonyl)-1-(4-nitro-1,3-dioxoisoindolin-2-yl)ethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate 
• 1384814-90-7 (S)-4-amino-2-[1-(3-ethoxy-4-glucopyranuroxy-phenyl)-2-methanefulfonyl-ethyl]-isoindole-1,3-dione 
• 1384967-25-2 C₃₁H₃₄N₂O₁₅S 

Relevant academic research and scientific papers

Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT

Chemotherapy of malign tumors is usually associated with serious side effects as common anticancer drugs lack selectivity. An approach to deal with this problem is the antibody-directed enzyme prodrug therapy (ADEPT) and the prodrug monotherapy (PMT). Her

Duocarmycin-based prodrugs for cancer prodrug monotherapy

The synthesis and biological evaluation of novel prodrugs based on the cytotoxic antibiotic duocarmycin SA (1) for a selective treatment of cancer using a prodrug monotherapy (PMT) are described. Transformation of the phenol 8 with the glucuronic acid benzyl ester trichloroacetimidate 9b followed by reaction with DMAI·HCl (10) gives the glucuronide 11b, which is deprotected to afford the desired prodrug 4a containing a glucuronic acid moiety. In addition, the prodrug 4b with a glucuronic methyl ester unit is prepared. The cytotoxicity of the glucuronides is determined using a HTCFA-assay with IC50 values of 610 nM for 4a and 3300 nM for 4b. In the presence of β-glucuronidase, 4a expresses an IC50 value of 0.9 nM and 4b of 2.1 nM resulting in QIC50 values of about 700 for 4a and 1600 for 4b.